Skip to content
10-Q

Quarterly Report

REGENEREX PHARMA, INC. RGPX

0001472375-25-000094

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Jul 7, 2025 281.43M sh
Operating Cash Flow Q1 2024 · Jun 30, 2025 −$477.94K
Operating Cash Flow Q1 2024 · Jun 30, 2024 −$55.33K
Cash And Equivalents Q1 2024 · Jun 30, 2025 $172.43K
Cash And Equivalents Q1 2024 · Mar 31, 2025 $653.03K
Stockholders Equity Q1 2024 · Jun 30, 2025 −$4.55M
Stockholders Equity Q1 2024 · Mar 31, 2025 −$4.16M
Stockholders Equity Q1 2024 · Jun 30, 2024 −$4.31M
Stockholders Equity Q1 2024 · Mar 31, 2024 −$4.06M
Current Liabilities Q1 2024 · Jun 30, 2025 $4.85M
Current Liabilities Q1 2024 · Mar 31, 2025 $4.92M
Total Liabilities Q1 2024 · Jun 30, 2025 $5.31M
Total Liabilities Q1 2024 · Mar 31, 2025 $5.42M
Current Assets Q1 2024 · Jun 30, 2025 $192.68K
Current Assets Q1 2024 · Mar 31, 2025 $653.38K
Total Assets Q1 2024 · Jun 30, 2025 $763.37K
Total Assets Q1 2024 · Mar 31, 2025 $1.26M
Net Income Q1 2024 · Jun 30, 2025 −$663.58K
Net Income Q1 2024 · Jun 30, 2024 −$272.56K
Operating Income Q1 2024 · Jun 30, 2025 −$633.78K
Operating Income Q1 2024 · Jun 30, 2024 −$254.28K